Helicobacter pylori infection and Peptic ulcers

From a western clinical standpoint, Helicobacter pylori infection is the dominant infectious driver of peptic ulcer disease (PUD). The organism’s urease activity neutralizes gastric acid at the mucosal surface, while flagella and adhesins allow penetration into the mucus layer. Virulence factors such as CagA and VacA, coupled with the host inflammatory response, erode epithelial defenses and alter acid regulation. Antral-predominant gastritis reduces somatostatin and increases gastrin, leading to acid hypersecretion that promotes duodenal gastric metaplasia and ulceration. Corpus-predominant gastritis can suppress acid and foster atrophic changes, with different clinical implications. Although ulcers also occur with NSAIDs/aspirin, critical illness, and rare hypersecretory states (e.g., Zollinger–Ellison syndrome), the intersection of H. pylori with NSAIDs is especially consequential: together they multiply the risk of ulcers and bleeding. Diagnosis follows a risk-stratified approach. In patients younger than about 55–60 without alarm features, noninvasive tests—13C urea breath test or monoclonal stool antigen—accurately detect infection. Endoscopy with biopsy (rapid urease testing, histology, and culture where available) is preferred with red flags, in older adults with new dyspepsia, or when gastric ulcers are suspected, both to diagnose and to exclude malignancy. Because PPIs, bismuth, and antibiotics can suppress the organism, they are withheld before testing when safe. Rising antibiotic resistance has shifted first-line therapy toward bismuth-containing quadruple regimens or non-bismuth concomitant combinations, tailored where possible to local resistance patterns or susceptibility testing. Confirmation of eradication—by breath or stool antigen testing at least four weeks after antibiotics and two weeks off PPIs—is recommended. Clinically, eradication plus acid suppression heals most ulcers and prevents relapse and bleeding. In complicated ulcers (e.g., bleeding), endoscopic hemostasis combined with high-dose PPI therapy reduces rebleeding. Preventive strategies include testing for and treating H. pylori before initiating long-term NSAIDs, minimizing NSAID exposure, smoking cessation, and addressing comorbid risks. The long-term outlook after successful eradication is excellent, with low reinfection rates in low-prevalence settings and meaningful reductions in gastric cancer risk.

Traditional healing systems frame ulcer symptoms within broader imbalances of digestive function and internal heat. In Traditional Chinese Medicine (TCM), epigastric pain, acid regurgitation, and irritability often reflect Stomach Heat, Damp-Heat in the Middle Jiao, or Liver qi constraint attacking the Stomach. H. pylori can be interpreted as a form of ‘heat-toxin’ that aggravates these patterns. Treatment principles include clearing heat, resolving dampness, harmonizing the Liver and Stomach, and protecting the mucosa. Herbs rich in berberine (e.g., Coptis/Huang Lian) are traditionally used to clear heat and toxin; modern studies suggest that berberine may modestly assist eradication when combined with standard antibiotics. Demulcents such as licorice (often used in deglycyrrhizinated form to minimize mineralocorticoid effects) soothe the gastric lining. Acupuncture points selected to regulate qi and relieve pain (e.g., Zusanli/ST36, Neiguan/PC6, Zhongwan/CV12) are used clinically to reduce epigastric discomfort and nausea. Ayurveda locates these conditions under Amlapitta—disturbed pitta and agni—manifesting as sour belching, burning, and pain. Management calms pitta and protects the gut using cooling, demulcent herbs (e.g., yashtimadhu/licorice, amla/Emblica officinalis) and mindful dietary routines. Naturopathic and integrative frameworks emphasize microbiome-friendly nutrition (fiber- and polyphenol-rich foods), avoidance of alcohol and tobacco, stress reduction, and targeted supplements such as probiotics and zinc-carnosine to support the mucosa. Integrative practice aligns with western priorities: eradicate H. pylori when present, suppress acid to heal the ulcer, and reduce cofactors like NSAIDs and smoking. Within that medical scaffold, carefully chosen adjuncts—probiotics to reduce antibiotic side effects, zinc-carnosine or DGL for mucosal comfort, and, where appropriate, berberine-containing botanicals—may support outcomes. Safety and collaboration are central: herbs can interact with medications (for example, berberine with cytochrome P450 substrates, or non-deglycyrrhizinated licorice raising blood pressure), and vulnerable groups (pregnancy, significant comorbidities) require extra caution. Open communication with healthcare providers allows a personalized, culturally respectful plan that marries evidence-based eradication with supportive traditional measures.